Author "Romain Altwegg"

articles+ search results

84 articles+ results

1 - 20
View results as:
Number of results to display per page

1. Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study [2023]

  • Aurelien Amiot, Anne Bourrier, Jean-Marc Gornet, Olivier Dewit, Stephane Nancey, Romain Altwegg, Vered Abitbol, David Laharie, Catherine Reenaers, Charlotte Gagnière, Anthony Buisson, Maria Nachury, Stephanie Viennot, Lucine Vuitton, Carmen Stefanescu, Philippe Marteau, Guillaume Bouguen, and Philippe Seksik
  • Infection Prevention in Practice, Vol 5, Iss 1, Pp 100267- (2023)
Subjects
Crohn's disease, Ulcerative colitis, Inflammatory bowel disease, Healthcare worker, SARS-CoV-2, Infectious and parasitic diseases, RC109-216, Public aspects of medicine, and RA1-1270
Abstract
Summary: Background: Whether healthcare workers with inflammatory bowel disease (IBD) are at increased risk of Novel coronavirus disease (COVID-19) due to occupational exposure is unknown. Aim: To assess the risk of COVID-19 in healthcare workers with IBD. Methods: A case control study enrolled 326 healthcare workers with IBD from 17 GETAID centres and matched non-healthcare workers with IBD controls (1:1) for gender, age, disease subtype and year of diagnosis. The study period was year 2020 during the COVID-19 outbreak. Results: In total, 59 COVID-19 were recorded among cases (n = 32) and controls (n = 27), including 2 severe COVID-19 (requiring hospitalization, mechanic ventilation) but no death. No difference was observed between healthcare workers and controls regarding the overall incidence rates of COVID-19 4.9 ± 2.2 vs. 3.8 ± 1.9 per 100 patient-semesters, P = 0.34) and the overall incidence rates of severe COVID-19 (0.6 ± 7.8 vs. 0.3 ± 5.5 per 100 patient-semesters, P = 0.42). In multivariate analysis in the entire study population, COVID-19 was associated with patients with body mass index > 30 kg/m2 (HR = 2.48, 95%CI [1.13–5.44], P = 0.02). Conclusion: Healthcare workers with IBD do not have an increased risk of COVID-19 compared with other patients with IBD.

2. A rapid and standardized workflow for functional assessment of bacterial biosensors in fecal samples [2022]

  • Ana Zúñiga, Geisler Muñoz-Guamuro, Lucile Boivineau, Pauline Mayonove, Ismael Conejero, Georges-Philippe Pageaux, Romain Altwegg, and Jerome Bonnet
  • Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Subjects
synthetic biology, diagnostics, whole-cell biosensor, engineered bacteria, metabolite detection, gut microbiome, Biotechnology, and TP248.13-248.65
Abstract
Gut metabolites are pivotal mediators of host-microbiome interactions and provide an important window on human physiology and disease. However, current methods to monitor gut metabolites rely on heavy and expensive technologies such as liquid chromatography-mass spectrometry (LC-MS). In that context, robust, fast, field-deployable, and cost-effective strategies for monitoring fecal metabolites would support large-scale functional studies and routine monitoring of metabolites biomarkers associated with pathological conditions. Living cells are an attractive option to engineer biosensors due to their ability to detect and process many environmental signals and their self-replicating nature. Here we optimized a workflow for feces processing that supports metabolite detection using bacterial biosensors. We show that simple centrifugation and filtration steps remove host microbes and support reproducible preparation of a physiological-derived media retaining important characteristics of human feces, such as matrix effects and endogenous metabolites. We measure the performance of bacterial biosensors for benzoate, lactate, anhydrotetracycline, and bile acids, and find that they are highly sensitive to fecal matrices. However, encapsulating the bacteria in hydrogel helps reduce this inhibitory effect. Sensitivity to matrix effects is biosensor-dependent but also varies between individuals, highlighting the need for case-by-case optimization for biosensors’ operation in feces. Finally, by detecting endogenous bile acids, we demonstrate that bacterial biosensors could be used for future metabolite monitoring in feces. This work lays the foundation for the optimization and use of bacterial biosensors for fecal metabolites monitoring. In the future, our method could also allow rapid pre-prototyping of engineered bacteria designed to operate in the gut, with applications to in situ diagnostics and therapeutics.

3. Retinal Microcirculation Changes in Crohn’s Disease Patients under Biologics, a Potential Biomarker of Severity: A Pilot Study [2022]

  • Eloi Debourdeau, Chloé Charmard, Isabelle Carriere, Julien Plat, Max Villain, Lucile Boivineau, Romain Altwegg, and Vincent Daien
  • Journal of Personalized Medicine, Vol 12, Iss 230, p 230 (2022)
Subjects
OCT angiography, fundus photographs, Crohn’s disease, cardiovascular disease, population-based study, retinal vascular network, and Medicine
Abstract
Crohn’s disease (CD) is associated with increased cardiovascular risk and the retinal microcirculation is a reflection of the systemic microcirculation. Is the retinal microcirculation altered in relation to the severity of Crohn’s disease? This cross-sectional case-controlled study was conducted in a university hospital center from November 2020 to February 2021. We prospectively included patients with moderate (biologic therapy) or severe (biologic therapy + peri-anal disease and/or digestive resection) CD and age- and sex-matched controls. Individuals with diabetes, renal disease, cardiovascular disease, ophthalmological history or poor quality images were excluded. All participants underwent OCT angiography (OCT-A) imaging (Optovue, Fremont, CA). Analysis of covariance was used. 74 CD patients (33 moderate, 41 severe) and 74 controls (66 (44.6%) men; mean (SD) age 44 (14) years) were included. Compared with the controls, the severe CD patients showed a significantly reduced mean foveal avascular zone area (p = 0.001), superficial macular capillary plexus vessel density (p = 0.009) and parafoveal thickness (p < 0.001), with no difference in mean superficial capillary flow index (p = 0.06) or deep macular capillary plexus vessel density (p = 0.67). The mean foveal avascular zone was significantly lower in the severe than the moderate CD patients (p = 0.010). OCT-A can detect alterations in retinal microcirculation in patients with severe versus moderate CD and versus age- and sex-matched controls.

4. The COVID-19 Pandemic Led to a Small Increase in Changed Mentality Regarding Infection Risk without Any Change in Willingness to Be Vaccinated in Chronic Diseases Patients [2021]

  • Cyril Breuker, Anne Marie Guedj, Mathilde Allan, Loick Coinus, Nicolas Molinari, Nicolas Chapet, François Roubille, Moglie Le Quintrec, Véronique Duhalde, Julien Jouglen, Philippe Cestac, Jean Marie Kinowski, Stéphanie Faure, Marie Faucanie, Laura Lohan, Maxime Villiet, Romain Altwegg, and Ariane Sultan
  • Journal of Clinical Medicine, Vol 10, Iss 3967, p 3967 (2021)
Subjects
people living with diabetes, vaccination coverage, COVID-19 pandemic, infection risk, chronic disease, and Medicine
Abstract
The objective of this study was to assess the impact of the COVID-19 pandemic on patients’ perceptions regarding infection risk and vaccination in subjects suffering from chronic diseases. A prospective observational multicentric study conducted from December 2020 to April 2021 in three French University Hospitals. Patients with chronic diseases were proposed to complete a questionnaire regarding the impact of the COVID-19 pandemic on infectious risk knowledge and vaccination. A total of 1151 patients were included and analyzed (62% of which were people with diabetes). The COVID-19 pandemic increased awareness of infectious risks by 19.3%, significantly more in people with diabetes (23.2%, from 54.4% to 67.0%, p < 0.01) when compared to the other high-risk patients (12.5%, from 50.5% to 56.8%, p = 0.06). Respectively, 30.6% and 16.5% of patients not up-to-date for pneumococcal and flu vaccines reported wanting to update their vaccination due to the COVID-19 pandemic. By contrast, the proportion of patients against vaccines increased during the COVID-19 pandemic (6.0% vs. 9.5%, p < 0.01). The COVID-19 pandemic has led to a small increase in awareness regarding the risks of infection in patients with chronic diseases, including people with diabetes, but without any change in willingness to be vaccinated. This underlines the urgent need to sensibilize people with diabetes to infection risk and the importance of vaccination.

5. TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease [2014]

  • Romain Altwegg and Thierry Vincent
  • Mediators of Inflammation, Vol 2014 (2014)
Subjects
Pathology and RB1-214
Abstract
Since their appearance in the armamentarium for inflammatory bowel disease (IBD) more than a decade ago, antitumor necrosis factor (TNF) inhibitors have demonstrated beneficial activity in induction and maintenance of clinical remission, mucosal healing, improvement in quality of life, and reduction in surgeries and hospitalizations. However, more than one-third of patients present primary resistance, and another one-third become resistant over time. One of the main factors associated with loss of response is the immunogenicity of anti-TNF biologics leading to the production of antidrug antibodies (ADAbs) accelerating their clearance. In this review we present the current state of the literature on the place of TNF and its blockage in the treatment of patients with IBD and discuss the usefulness of serum trough levels and ADAb monitoring in the optimization of anti-TNF therapies.

6. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study [2021]

  • Mathurin Fumery, Jérôme Filippi, Vered Abitbol, Amélie Biron, David Laharie, Melanie Serrero, Romain Altwegg, Yoram Bouhnik, Laurent Peyrin‐Biroulet, Cyrielle Gilletta, Xavier Roblin, Guillaume Pineton de Chambrun, Lucine Vuitton, Anne Bourrier, Stephane Nancey, Jean‐Marc Gornet, Stephane Nahon, Guillaume Bouguen, Stephanie Viennot, Maria Nachury, Aurelien Amiot, Franck Brazier, Clara Yzet, Xavier Hebuterne, Guillaume Cadiot, Hedia Brixi, Pauline Rivière, Florian Poullenot, Xavier Treton, Carmen Stefanescu, Camille Zallot, Laurent Beaugerie, Philippe Seksik, Harry Sokol, Julien Kirchgesner, Gilles Boschetti, Bernard Flourié, Claire Gay, Pauline Danion, Chloe Venturin, Matthieu Allez, Clotilde Baudry, Benjamin Pariente, Pauline Wils, Charlotte Gagnière, and Jenny Tannoury
  • Alimentary Pharmacology & Therapeutics. 54:944-951
Subjects
Pharmacology (medical), Gastroenterology, and Hepatology

7. Real-life pilot study on the impact of the telemedicine platform EasyMICI–MaMICI® on quality of life and quality of care in patients with inflammatory bowel disease [2021]

  • Guillaume Bonnaud, Audrey Haennig, Romain Altwegg, Bénédicte Caron, Lucile Boivineau, Camille Zallot, Cyrielle Gilleta de Saint-Joseph, Jacques Moreau, Florent Gonzalez, Didier Reynaud, Patrick Faure, Philippe Aygalenq, Jean Marc Combis, and Laurent Peyrin-Biroulet
  • Scandinavian Journal of Gastroenterology. 56:530-536
Subjects
Gastroenterology

8. Alcohol Consumption the Day of Liver Transplantation for Alcohol‐Associated Liver Disease Does Not Affect Long‐Term Survival: A Case‐Control Study [2020]

  • José Ursic-Bedoya, Olivier Boillot, Sébastien Dharancy, Claire Vanlemmens, Georges-Philippe Pageaux, Lucy Meunier, Stéphanie Faure, Claire Francoz, Mohamed C. Belkacemi, Jérôme Dumortier, Magdalena Meszaros, Astrid Herrero, Sarah Shili‐Masmoudi, Camille Besch, Romain Altwegg, and Hélène Donnadieu-Rigole
  • Liver Transplantation. 27:34-42
Subjects
Transplantation, Hepatology, Surgery, Medicine, business.industry, business, Gastroenterology, medicine.medical_specialty, Case-control study, Internal medicine, Cirrhosis, medicine.disease, Alcohol, chemistry.chemical_compound, chemistry, Alcohol Abstinence, Odds ratio, Liver transplantation, medicine.medical_treatment, Liver disease, and Urine
Abstract
Alcohol abstinence before liver transplantation (LT) for alcohol-associated liver disease (ALD) is required for every candidate. Some listed patients might relapse, resulting in LT for patients nonabstinent during the pretransplant period. Long-term survival outcomes of these patients have never been studied. We sought to determine whether alcohol consumption on the day of the LT influenced long-term survival after LT. We conducted a retrospective case-control study among French LT centers. Cases were defined as recipients between January 1995 and December 2007 having positive blood and/or urine alcohol levels the day of LT. Each case was paired with 2 controls corresponding to patients transplanted for ALD during the same trimester. Patients were classified into 3 categories per alcohol consumption: abstainers, occasional or transitory excessive consumers, or patients with a sustained excessive consumption (daily consumption >20-30 g/day). During the study period, 3052 LTs for ALD were conducted in France. We identified 42 cases paired with 84 controls. Median blood alcohol level was 0.4 g/L (range 0.1-4.1 g/L) and median urine alcohol level was 0.2 g/L (range 0.1-2.0 g/L). Median follow-up period until death or censoring was 12.9 years (CI95% = [12.3; 13.6]). Long-term survival was not different between the groups. Relapse to any alcohol consumption rate was higher in the case group (59.5%) than in the control group (38.1%, odds ratio 2.44; CI95% = [1.13; 5.27]), but sustained excessive consumption was not significantly different between the groups (33.3% versus 29.8% in case and control groups respectively, χ2 = 0.68). Rates of recurrent cirrhosis and cirrhosis-related deaths were more frequent in the case group. Liver transplantation for nonabstinent patients during the immediate pretransplant period does not result in impaired long-term survival despite higher relapse and recurrent cirrhosis rates.

9. La dysbiose intestinale dans les maladies inflammatoires chroniques de l’intestin [2020]

  • Anne Laure Michon and Romain Altwegg
  • Revue Francophone des Laboratoires. 2020:47-54
Subjects
Biochemistry, medical, Medical Laboratory Technology, Analytical Chemistry, Biology, Molecular biology, Transplantation, Faecalibacterium prausnitzii, and biology.organism_classification
Abstract
Resume Le microbiote intestinal joue un role fondamental dans la pathogenie des maladies inflammatoires chroniques de l’intestin (Mici), et de nombreux travaux chez l’animal et l’humain retrouvent ce concept de dysbiose intestinale, a la fois pour le microbiote bacterien, mais probablement egalement pour le microbiote fongique et viral. De nombreuses etudes retrouvent une modification du microbiote bacterien chez les patients atteints de Mici, caracterise par une reduction de la diversite bacterienne, avec une diminution du phylum des Firmicutes (dont notamment Faecalibacterium prausnitzii) et une augmentation du phylum des Proteobacteria. Les etudes actuelles sur la transplantation de microbiote intestinal devraient permettre de mieux comprendre le role de la dysbiose dans ces pathologies.

10. Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group [2020]

  • Maria Nachury, Yoram Bouhnik, Melanie Serrero, Jerome Filippi, Xavier Roblin, Julien Kirchgesner, Guillaume Bouguen, Denis Franchimont, Guillaume Savoye, Anthony Buisson, Edouard Louis, Stephane Nancey, Vered Abitbol, Jean-Marie Reimund, Olivier DeWit, Lucine Vuitton, Nicolas Matthieu, Laurent Peyrin-Biroulet, Cyrielle Gilletta, Sara Tadbiri, Matthieu Allez, Stephanie Viennot, Arnaud Bourreille, David Laharie, Aurelien Amiot, Charlotte Gagniere, Jenny Tannoury, Benjamin Pariente, Pauline Wils, Carmen Stefanescu, Xavier Treton, Xavier Hébuterne, Nadia Arab, Virginie Cluzeau, Emilie Del Tedesco, Laurent Beaugerie, Philippe Seksik, Anne Bourrier, Cecilia Landmann, Harry Sokol, Laurent Siproudhis, Marie DeWitte, Catherine Reenaers, Gilles Boschetti, Claire Gay, Pauline Danion, Bernard Flourié, Georgia Malamut, Benedicte Caron, Olivier DeWitt, Nicolas Mathieu, Sandie Pestour, Camille Zallot, Jean-Marc Gornet, Clotilde Baudry, Caroline Trang-Poisson, Nina Dib, Hedi Brixi, Guillaume Cadiot, Medina Boualit, Claire Painchart, Laurianne Plastaras, Romain Altwegg, Lucile Boivineau, Mathurin Fumery, Ludovic Caillo, Pauline Riviere, Florian Poullenot, Benoit Coffin, Henri Duboc, Stephane Nahon, Noemie Tavernier, Marion Simon, Baya Coulibaly, Morgane Amil, Duveau Nicolas, Sherine Khater, Mehdi Kaassis, Felix Goutorbe, Driffa Moussata, and Laurence Picon
  • Digestive and Liver Disease. 53:434-441
Subjects
Gastroenterology, Hepatology, Cross-sectional study, Crohn's disease, medicine.disease, medicine, Health professionals, Tertiary care, Family medicine, medicine.medical_specialty, business.industry, business, Ulcerative colitis, Adverse effect, Disease, Inflammatory bowel disease, digestive system diseases, and digestive system
Abstract
Background Patients’ experience with healthcare professionals could influence their clinical outcomes. Aims To assess inflammatory bowel disease (IBD) patients’ experience with their disease, their treatment and their relationship with their physician. Methods A one-week cross-sectional study was conducted in 42 IBD centres. 2011 consecutive outpatients with IBD completed an anonymous self-report questionnaire assessing their experience with and knowledge of IBD. Results A quantitative assessment of the doctor-patient relationship revealed that patients’ knowledge of IBD and IBD treatment ranged from 7.4 to 8.3 out of 10. In addition to IBD physicians, other sources of information about IBD and current treatment mainly included the internet (80% and 63%, respectively) and general practitioners (61% and 54%). Knowledge about education programmes (28%) was poor, resulting in a lack of willingness to further use these resources (25%). Concerns about IBD treatment were raised in 76% of patients, mostly related to the fear of adverse events (47%) and a lack of efficacy (33%). The need of alternative healthcare professionals was reported by 89% of the sample. Conclusion In a large cohort of patients, we highlighted gaps in the management of patients with IBD regarding the need for higher-quality information and the implementation of alternative healthcare professionals.

11. Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients with Type 2 Diabetes [2021]

  • Jean‐Luc Faillie, Hui Yin, Oriana H. Y. Yu, Astrid Herrero, Romain Altwegg, Christel Renoux, and Laurent Azoulay
  • Clinical Pharmacology & Therapeutics.
Subjects
Pharmacology (medical) and Pharmacology

12. Impact of an Education Programme on IBD Patients’ Skills: Results of a Randomised Controlled Multicentre Study [ECIPE] [2020]

  • Kristell Desseaux, Jean-Louis Dupas, Harry Sokol, L Caillo, S Orempuller, Martine Leconte, Xavier Roblin, Souheyla Mezrag Biskri, Getaid, Laura Armengol-De Beir, Bruno Mesnard, Jacques Moreau, Geraldine Herbet, Benjamin Pariente, Annie Bornet, Isabelle Nion-Larmurier, Caroline Trang-Poisson, Joséphanne Romarin, Gaëlle Vienney, Nassim Hammoudi, Sylvie Chevret, K Desseaux, F Carbonnel, Delphine Coutarel, Suzanna Ostrec, Nadia Hoyeau, Julien Blot, Marianne Lassailly, Katia Ferreira, J C Grimaud, Nadia Arab, Laetitia Legoux, Isabelle Lutgen, Noémie Tavernier, Aurore Paput, Franck Brazier, R Altwegg, Stéphanie Challier, C Stefanescu, X Hébuterne, L Marthey, Magalie Chauvigneau, Nathalie Descrouet, Mathurin Fumery, A Aubourg, N Hammoudi, Regine Berolo, Laurent Peyrin-Biroulet, Lysiane Marthey, Mathieu Allez, Andrée Nisard, Alexandre Aubourg, Yoram Bouhnik, Nelly Benard, J Moreau, Benoit Coffin, Emilie Del Tedesco, Arnaud Bourreille, Marion Simon, Philippe Seksik, X Roblin, Guillaume Savoye, Béatrice Boucard, B Mesnard, Julien Kirchgesner, Patrick Faure, Leïla Chedouba, Cécilia Landman, Joëlle Bonnet, Valérie Kail, Emilie Bergereau, Elise Foloppe, Marion Vincent, Carmen Stefanescu, Clotilde Debove, M Simon, Jérôme Filippi, Jean-Charles Grimaud, Evalyne Eyraud, Mylène Ducerne, S Nahon, Anne Bourrier, Yann Parc, B Coffin, P Seksik, Marie-Christine Lorin, Gwenola Vernier, Xavier Treton, C Baudry, Sandra Orempuller, Najim Chafai, Stéphane Nahon, M Fumery, Jérémie H. Lefevre, Maria Nachury, Amine Rahill, Charles Lamblin, Clotilde Baudry, Franck Carbonnel, Laurent Beaugerie, Audrey Haenning, M Nachury, Elise Kerdreux, C Trang-Poisson, Floriane Verhaeghe, Jean-Félix Lepasteur, Virginie Cluzeau, Xavier Hébuterne, G Savoye, Valérie Lebayle, Laurence Picon, Matthieu Allez, L Peyrin-Biroulet, and Romain Altwegg
  • Journal of Crohn's and Colitis. 15:432-440
Subjects
Gastroenterology, General Medicine, Randomized controlled trial, law.invention, law, Multivariate analysis, Internal medicine, medicine.medical_specialty, medicine, Randomization, Disease course, business.industry, business, Quality of life, Inflammatory bowel disease, medicine.disease, Clinical endpoint, and Disease
Abstract
Background Better patient knowledge on inflammatory bowel disease [IBD] could improve outcome and quality of life. The aim of this study was to assess if an education programme improves IBD patients’ skills as regards their disease. Methods The GETAID group conducted a prospective multicentre randomised controlled study. IBD patients were included at diagnosis, or after a significant event in the disease course. Patients were randomised between ‘educated’ or control groups for 6 months. Education was performed by trained health care professionals. A psycho-pedagogic score [ECIPE] was evaluated by a ‘blinded’ physician at baseline and after 6 and 12 months [M6 and M12]. The primary endpoint was the increase of ECIPE score at M6 of more than 20%. Results A total of 263 patients were included in 19 centres (male:40%; median age:30.8; Crohn’s disease [CD]:73%). Of these, 133 patients were randomised into the educated group and 130 into the control group. The median relative increase in ECIPE score at M6 was higher in the educated group as compared with the control group (16.7% [0–42.1%] vs 7% [0–18.8%], respectively, p = 0.0008). The primary endpoint was met in 46% vs 24% of the patients in the educated and control groups, respectively [p = 0.0003]. A total of 92 patients met the primary endpoint. In multivariate analysis, predictors of an increase of at least 20% of the ECIPE score were randomisation in the educated group (odds ratio [OR] = 2.59) and no previous surgery [OR = 1.92]. Conclusions These findings support the set-up of education programmes in centres involved in the management of IBD patients.

13. Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn’s Disease: A Multicentre Study [2020]

  • Bernard Flourié, Florian Poullenot, Xavier Treton, Cyrielle Gilletta, Lieven Pouillon, Anthony Buisson, Momar Diouf, Stephanie Viennot, Lucile Boivineau, Franck Brazier, Mathurin Fumery, David Laharie, Laurent Peyrin-Biroulet, Laurent Siproudhis, Xavier Roblin, Stéphane Nancey, Romain Altwegg, Jérôme Filippi, Anne Bozon, Guillaume Bouguen, and Pauline Veyrard
  • Journal of Crohn's and Colitis. 15:222-227
Subjects
Gastroenterology, General Medicine, Medicine, business.industry, business, Calprotectin, Adverse effect, Internal medicine, medicine.medical_specialty, Colonoscopy, medicine.diagnostic_test, Every Four Weeks, Cohort study, Interquartile range, Crohn's disease, medicine.disease, Ustekinumab, and medicine.drug
Abstract
Background The approved maintenance regimens for ustekinumab in Crohn’s disease [CD] are 90 mg every 8 or 12 weeks. Some patients will respond partially to ustekinumab or will experience a secondary loss of response. It remains poorly known if these patients may benefit from shortening the interval between injections. Methods All patients with active CD, as defined by Harvey–Bradshaw score ≥ 4 and one objective sign of inflammation [C-reactive protein > 5 mg/L and/or faecal calprotectin > 250 µg/g and/or radiological and/or endoscopic evidence of disease activity] who required ustekinumab dose escalation to 90 mg every 4 weeks for loss of response or incomplete response to ustekinumab 90 mg every 8 weeks were included in this retrospective multicentre cohort study. Results One hundred patients, with a median age of 35 years [interquartile range, 28–49] and median disease duration of 12 [7–20] years were included. Dose intensification was performed after a median of 5.0 [2.8–9.0] months of ustekinumab treatment and was associated with corticosteroids and immunosuppressants in respectively 29% and 27% of cases. Short-term clinical response and clinical remission were observed in respectively 61% and 31% after a median of 2.4 [1.3–3.0] months. After a median follow-up of 8.2 [5.6–12.4] months, 61% of patients were still treated with ustekinumab, and 26% were in steroid-free clinical remission. Among the 39 patients with colonoscopy during follow-up, 14 achieved endoscopic remission [no ulcers]. At the end of follow-up, 27% of patients were hospitalized, and 19% underwent intestinal resection surgery. Adverse events were reported in 12% of patients, including five serious adverse events. Conclusion In this multicentre study, two-thirds of patients recaptured response following treatment intensification with ustekinumab 90 mg every 4 weeks.

14. Segmental Colectomy for Ulcerative Colitis: Is There a Place in Selected Patients Without Active Colitis? An International Multicentric Retrospective Study in 72 Patients [2020]

  • Yves Panis, Valérie Bridoux, Fabrizio Michelassi, Mathurin Fumery, Antonino Spinelli, L Cohen, Pär Myrelid, Xavier Treton, Quentin Denost, Matteo Frasson, A Frontali, E Louis, Gilberto Poggioli, Giuseppe S. Sica, Silvio Danese, Eloy Espín, Laura Beyer-Berjot, D Laharie, Philippe Zerbib, Gianluca M. Sampietro, Stéphane Nancey, Romain Altwegg, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de chirurgie digestive [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Linköping University (LIU), PoliclinicoTor Vergata - Fondatione PTV, Policlinico S. Orsola-malpighi, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO)-Servizio sanitario regionale Emilia-Romagna, Vall d'Hebron University Hospital [Barcelona], Assistance Publique - Hôpitaux de Marseille (APHM), CHU Bordeaux [Bordeaux], Department of Colorectal Surgery, Humanitas Research Hospital, Milano, Italy., Hôpital Claude Huriez [Lille], CHU Lille, Department of Surgery, IBD Unit, Luigi Sacco University Hospital, Milano, Italy., University Hospital La Fe, Digestive Surgery, Valencia, Spain., Centre Hospitalier Universitaire de Liège (CHU-Liège), Department of Gastroenterology, Humanitas Research Hospital, Milano, Italy., Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, CHU Pessac, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), and Agogo Presbyterian Hospital [GHANA]
  • Journal of Crohn's and Colitis
    Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2020, ⟨10.1093/ecco-jcc/jjaa107⟩
Subjects
Gastroenterology, General Medicine, Right Colectomy, Medicine, business.industry, business, Ulcerative colitis, medicine.disease, Anastomosis, Dysplasia, Colitis, Diverticulitis, Internal medicine, medicine.medical_specialty, Retrospective cohort study, Sigmoidectomy, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, postoperative flare, Segmental colectomy, ulcerative colitis, and Settore MED/18
Abstract
Background and Aims The aim of this study was to report a multicentric experience of segmental colectomy [SC] in ulcerative colitis [UC] patients without active colitis, in order to assess if SC can or cannot represent an alternative to ileal pouch-anal anastomosis [IPAA]. Methods All UC patients undergoing SC were included. Postoperative complications according to ClavienDindo’s classification, long term results, and risk factors for postoperative colitis and reoperation for colitis on the remnant colon, were assessed. Results: A total of 72 UC patients underwent: sigmoidectomy [n = 28], right colectomy [n = 24], proctectomy [n = 11], or left colectomy [n = 9] for colonic cancer [n = 27], ‘diverticulitis’ [n = 17], colonic stenosis [n = 5], dysplasia or polyps [n = 8], and miscellaneous [n = 15]. Three patients died postoperatively and 5/69 patients [7%] developed early flare of UC within 3 months after SC. After a median followup of 40 months, 24/69 patients [35%] were reoperated after a median delay after SC of 19 months [range, 2–158 months]: 22/24 [92%] underwent total colectomy and ileorectal anastomosis [n = 9] or total coloproctectomy [TCP] [n = 13] and 2/24 [8%] an additional SC. Reasons for reoperation were: colitis [n = 14; 20%], cancer [n = 3] or dysplasia [n = 3], colonic stenosis [n = 1], and unknown reasons [n = 3]. Endoscopic score of colitis before SC was Mayo 23 in 5/5 [100%] patients with early flare vs 15/42 without early flare [36%; p = 0.0101] and in 9/12 [75%] patients with reoperation for colitis vs 11/35 without reoperation [31%; p = 0.016]. Conclusions After segmental colectomy in UC patients, postoperative early colitis is rare [7%]. Segmental colectomy could possibly represent an alternative to IPAA in selected UC patients without active colitis.

15. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study [2020]

  • Mireille Simon, Felix Goutorbe, Laurent Peyrin-Biroulet, Xavier Roblin, David Laharie, Stéphane Nancey, Romain Altwegg, Mathurin Fumery, L Caillo, Pauline Rivière, Marianne Hupé, Guillaume Bouguen, Jérôme Filippi, and Arnaud Bourreille
  • Alimentary Pharmacology & Therapeutics. 51:852-860
Subjects
Pharmacology (medical), Gastroenterology, Hepatology, Infliximab, medicine.drug, medicine, Adalimumab, Golimumab, Discontinuation, business.industry, business, Ulcerative colitis, medicine.disease, Internal medicine, medicine.medical_specialty, Vedolizumab, Retrospective cohort study, and Odds ratio
Abstract
BACKGROUND Few data exist to help select a second biologic agent in patients with refractory ulcerative colitis (UC). AIM To compare the efficacy of infliximab (IFX) and vedolizumab (VDZ) in UC patients who failed a first subcutaneous anti-tumor necrosing factor (TNF) agent. METHODS Consecutive UC patients from 12 French centres starting IFX or VDZ after at least one injection of adalimumab or golimumab have been included in a retrospective study. Outcomes were clinical remission at week 14, survival without treatment discontinuation and survival without UC-related event. RESULTS Among the 225 patients included, clinical remission at week 14 was achieved in 40/154 (26%) patients treated with IFX and in 35/71 (49%) treated with VDZ (P = 0.001). After a propensity score matching analysis, this difference remained significant (odds ratio: 1.67; 95% confidence interval: 1.08-2.56; P = 0.02). With a median follow-up of 117 weeks, survival rates without treatment discontinuation at years 1 and 3 were 50% and 29% with IFX, and 80% and 55% with VDZ, respectively (P

16. Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study [2020]

  • Morgane Amil, Mathias Vidon, Laurent Beaugerie, Hélène Rousseau, Maria Nachury, Catherine Reenaers, Aurelien Amiot, Grégory Dubourg, Anne-Laure Pelletier, Lucas Guillo, David Laharie, Vered Abitbol, Felix Goutorbe, Stephanie Viennot, Mathieu Uzzan, Cédric Baumann, Laurent Peyrin-Biroulet, Mélanie Serrero, Anthony Buisson, Christian Rabaud, Jérôme Filippi, Stéphane Nancey, Romain Altwegg, Ludovic Caillo, Michael T. Collins, Laurence Picon, Jean-Marc Gornet, and Alban Benezech
  • Clinical Gastroenterology and Hepatology.
Subjects
Gastroenterology, Hepatology, Internal medicine, medicine.medical_specialty, medicine, Crohn's disease, medicine.disease, Retrospective cohort study, Concomitant, Intestinal mucosa, Inflammatory bowel disease, Disease, Hazard ratio, business.industry, business, Ulcerative colitis, and digestive system diseases
Abstract
Background and aims Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is a rare situation, the intersection between HIV and IBD remains unclear, especially the impact of HIV infection on the course of IBD, and the drug safety profile is unknown. Methods We conducted a multicenter retrospective cohort study between January 2019 and August 2020. All adult patients with IBD and concomitant HIV infection were included. Each IBD patient with HIV was matched to two HIV-uninfected IBD patients. Results Overall, 195 patients with IBD were included, including 65 HIV-infected patients and 130 without HIV infection. Of the 65 infected patients, 22 (33.8%) required immunosuppressants and 31 (47.7%) biologics. In the HIV-infected group, the need for immunosuppressants (p = 0.034 for CD and p=0.012 for UC) and biologics (p = 0.004 for CD and p=0.008 for UC) was significantly lower. The disease course, using a severity composite criterion, was not significantly different between the two groups for CD (hazard ration (HR) = 1.3 [0.7; 2.4], p=0.45) and UC (HR, 1.1 [0.5; 2.7], p=0.767). The overall drug safety profile was statistically similar between the two groups. Conclusion Although HIV-infected patients receive less treatments, the course of their IBD did not differ than uninfected, suggesting that HIV infection might attenuate IBD. The drug safety profile is reassuring, allowing physician to treat these patients according to current recommendations.

17. Endoscopic balloon dilation of colorectal strictures complicating Crohn’s disease: a multicenter study [2020]

  • L. Poincloux, Marion Tilmant, Guillaume Savoye, Clara Yzet, Lucile Boivineau, Florian Poullenot, Mélanie Serrero, Jérôme Filippi, Benjamin Pariente, Mathurin Fumery, David Laharie, P Basile, Laurent Peyrin-Biroulet, Ariane Desjeux, Guillaume Bouguen, Adnane Lamrani, Maria Nachury, Anthony Buisson, Pierre Vanelslander, Franck Brazier, Xavier Hébuterne, Romain Altwegg, Lucine Vuitton, Eric Le Balch, Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Hôpital Nord [CHU - APHM], Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre Hospitalier Universitaire de Nice (CHU Nice), Polyclinique Saint-Claude, CHU Gabriel Montpied (CHU), CHU Clermont-Ferrand, Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato-gastro-entérologie [CHRU Nancy], and Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
  • Clinics and Research in Hepatology and Gastroenterology
    Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2020, pp.101561. ⟨10.1016/j.clinre.2020.10.006⟩
Subjects
Crohn’s disease, colonic strictures, endoscopic balloon dilatation, [SDV]Life Sciences [q-bio], Gastroenterology, Hepatology, Anastomosis, Surgery, medicine.medical_specialty, medicine, Logistic regression, Retrospective cohort study, Disease, business.industry, business, Crohn's disease, medicine.disease, Interquartile range, Balloon dilation, Asymptomatic, and medicine.symptom
Abstract
International audience; INTRODUCTION: While endoscopic balloon dilation (EBD) is widely used to manage ileal strictures, EBD of colorectal strictures remains poorly investigated in Crohn’s disease (CD). METHODS: We performed a retrospective study that included all consecutive CD patients who underwent EBD for native or anastomotic colorectal strictures in 9 tertiary centers between 1999 and 2018. Factors associated with EBD failure were also investigated by logistic regression. RESULTS: Fifty-seven patients (25 women, median age: 36 years (InterQuartile Range, 31-48) were included. Among the 60 strictures, 52 (87%) were native, 39 (65%) measured < 5 cm and the most frequent location was the left colon (27%). Fifty-seven (95%) were non-passable by the scope and 35 (58%) were ulcerated. Among the 161 EBDs performed (median number of dilations per stricture: 2, IQR 1-3), technical and clinical success were achieved for 79% (n = 116/147) and 77% (n = 88/115), respectively. One perforation occurred (0.6% per EDB and 2% per patient). After a median follow-up of 4.3 years (IQR 2.0-8.4), 24 patients (42%) underwent colonic resection and 24 (42%) were asymptomatic without surgery. One colon lymphoma and one colorectal cancer were diagnosed (3.5% of patients) from endoscopic biopsies and at the time of surgery, respectively. No factor was associated with technical or clinical success. CONCLUSION: EDB of CD-associated colorectal strictures is feasible, efficient and safe, with more than 40% becoming asymptomatic without surgery.

18. Impact of gastric electrical stimulation on economic burden of refractory vomiting: a French nationwide multicentre study [2020]

  • Guillaume Gourcerol, Benoit Coffin, Bruno Bonaz, Hélène Hanaire, Stanislas Bruley Des Varannes, Frank Zerbib, Robert Caiazzo, Jean Charles Grimaud, François Mion, Samy Hadjadj, Paul Valensi, Lucine Vuitton, Guillaume Charpentier, Alain Ropert, Romain Altwegg, Philippe Pouderoux, Etienne Dorval, Michel Dapoigny, Henri Duboc, Pierre Yves Benhamou, Aurélie Schmidt, Nathalie Donnadieu, Philippe Ducrotte, Bruno Guerci, Helene Hanaire, Stanislas Bruley des Varannes, Francois Mion, Aurelie Schmidt, Nathalie Donadieu, Philippe Ducrotté, Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de physiologie digestive, urinaire, respiratoire et de l'exercice [CHU Rouen], Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Toulouse [Toulouse], Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire de Lille (CHU de Lille), Centre d'Investigation Clinique [Hôpital de la Conception - APHM] (CIC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), CHU de Lyon, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Universitaire de Besançon (CHU Besançon), Centre Hospitalier Sud Francilien [Corbeil-Essonnes] (CH Sud Francilien), Centre Hospitalier Universitaire de Rennes (CHU Rennes), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Clermont-Ferrand, STEVE CONSULTANTS 69600 OULLINS., Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre Hospitalier Universitaire de Nancy (CHU Nancy), and Enterra Research Group
  • Clinical Gastroenterology and Hepatology
    Clinical Gastroenterology and Hepatology, WB Saunders, 2020, ⟨10.1016/j.cgh.2020.11.011⟩
Subjects
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Gastroenterology, Hepatology, Medicine, business.industry, business, Vomiting, medicine.symptom, Cost effectiveness, Refractory, Body mass index, Gastroparesis, medicine.disease, Nausea, Internal medicine, medicine.medical_specialty, Quality of life, and Adverse effect
Abstract
Background Medico-economic data of patients suffering from chronic nausea and vomiting are lacking. In these patients, gastric electrical stimulation (GES) is an effective, but costly treatment. Aim The aim of this study was to assess the efficacy, safety and medico-economic impact of Enterra™ therapy in patients with chronic medically refractory nausea and vomiting. Methods Data were collected prospectively from patients with medically refractory nausea and/or vomiting, implanted with an Enterra™ device and followed for two years. Gastrointestinal quality of life index (GIQLI) score, vomiting frequency, nutritional status and safety were evaluated. Direct and indirect expenditure data were prospectively collected in diaries. Results Complete clinical data were available for142 patients (60 diabetic, 82 non-diabetic) and medico-economic data were available for 96 patients (36 diabetic, 60 non-diabetic), 24 months after implantation. GIQLI score increased by 12.1± 25.0 points (p Conclusion Enterra™ therapy is an effective, safe and cost-effective option for patients with refractory nausea and vomiting. ClinicalTrials gov Identifier: NCT00903799

19. 457 ADALIMUMAB FOR PATIENTS WITH CROHN'S DISEASE COMPLICATED BY INTRA-ABDOMINAL ABSCESS : LONG-TERM RESULTS OF THE MICA STUDY [2021]

  • Guillaume Pineton De Chambrun, Benjamin Pariente, Philippe Seksik, Romain Altwegg, Lucine Vuitton, Carmen Stefanescu, Stephane Nancey, Alexandre Aubourg, Melanie Serrero, Laurent Peyrin-Biroulet, Jerome Filippi, Stephanie Viennot, Vered Abitbol, Medina Boualit, Arnaud Bourreille, Maria Nachury, Jacques Moreau, Anthony Buisson, Xavier Roblin, Nina Dib, kristell Desseaux, Georgia Malamut, Aurelien Amiot, Magaly Zappa, Jerome Lambert, and Yoram Bouhnik
  • Gastroenterology. 160:S-92
Subjects
Gastroenterology and Hepatology

20. Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study [2019]

  • B Morel, Sylvain Ambregna, Lucile Boivineau, E. Del Tedesco, L Thomassin, Abitbol, Mélanie Serrero, Bérenger Martin, Caroline Trang, Cyrielle Gilletta, J B Danset, Maria Nachury, Aurelien Amiot, Guillaume Perrod, Stéphanie De Montigny, Marion Simon, Alain Attar, Antoine Blain, Jérôme Filippi, T Degand, Xavier Dray, Fanny Vaurie, Camille Zallot, Romain Altwegg, Stéphanie François, D Colin, Romain Gerard, Rossi, P Ah-Soune, Stéphane Koch, Stephanie Viennot, L Plastaras, Lucine Vuitton, Belinda Aider, Khadija Agouzal, Philippe Aygalenq, Julien Branche, B Winkfield, Philippe Bulois, Arnaud Boureille, Jonathan Levy, Anne-Laure Parmentier, C Briot, Guillaume Bonnaud, Patrick Faure, Alban Benezech, Clea Rouillon, Laurent Peyrin-Biroulet, and L Caillo
  • Journal of Crohn's and Colitis. 13:1121-1130
Subjects
Gastroenterology, General Medicine, Inflammatory bowel disease, medicine.disease, medicine, business.industry, business, Colonoscopy, medicine.diagnostic_test, Adverse effect, Low volume, Tolerability, Internal medicine, medicine.medical_specialty, Inflammatory Bowel Diseases, Observational study, Sodium picosulfate, chemistry.chemical_compound, and chemistry
Abstract
Background Standard high-volume polyethylene glycol [PEG] bowel preparations [PEG-4L] are recommended for patients with inflammatory bowel disease [IBD] undergoing colonoscopy. However, low-volume preparations [≤2 L of active volume] are often used in clinical practice. The aim of this study was to evaluate the efficacy, tolerability, and safety of the various bowel preparations for patients with IBD, including low-volume preparations. Methods We conducted a French prospective multicentre observational study over a period of 1 month. Patients aged 18–75 years with IBD with an indication of colonoscopy independent of the study were enrolled. The choice of the preparation was left to the investigators, as per their usual protocol. The patients’ characteristics, disease, and colonoscopy characteristics were recorded, and they were given self-reported questionnaires. Results Twenty-five public and private hospitals enrolled 278 patients. Among them, 46 had a disease flare and 41 had bowel stenoses. Bowel preparations for colonoscopy were as follows: 42% received PEG-2L, 29% received sodium picosulfate [Pico], 15% received PEG-4L, and 14% had other preparations. The preparation did not reach the Boston’s score efficacy outcome in the PEG-4L group in 51.2% of the patients [p = 0.0011]. The preparation intake was complete for 59.5% in the PEG-4L group, compared with 82.9% in the PEG-2L group and 93.8% in the Pico group [p < 0.0001]. Tolerability, as assessed by the patients’ VAS, was significantly better for both Pico and PEG-2L compared with PEG-4L, and better for Pico compared with PEG-2L [p = 0.008; p = 0.0003]. In multivariate analyses, low-volume preparations were independent factors of efficacy and tolerability. Adverse events occurred in 4.3% of the patients. Conclusions Preparations with PEG-2L and Pico were equally safe, with better efficacy and tolerability outcomes compared with PEG-4L preparations. The best efficacy/tolerance/safety profile was achieved with the Pico preparation.

Catalog

Books, media, physical & digital resources
See catalog results

Guides

Course- and topic-based guides to collections, tools, and services.
Search ""Romain Altwegg"" in all guide pages